-DOCSTART- -X- O
There -X- _ O
is -X- _ O
great -X- _ O
interest -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
Ab-inducing -X- _ O
subunit -X- _ O
vaccines -X- _ O
targeting -X- _ O
infections -X- _ O
, -X- _ O
including -X- _ O
HIV -X- _ O
, -X- _ O
malaria -X- _ O
, -X- _ O
and -X- _ O
Ebola. -X- _ O
We -X- _ O
previously -X- _ O
reported -X- _ O
that -X- _ O
adenovirus -X- _ O
vectored -X- _ O
vaccines -X- _ O
are -X- _ O
potent -X- _ O
in -X- _ O
priming -X- _ O
Ab -X- _ O
responses -X- _ O
, -X- _ O
but -X- _ O
uncertainty -X- _ O
remains -X- _ O
regarding -X- _ O
the -X- _ O
optimal -X- _ O
approach -X- _ O
for -X- _ O
induction -X- _ O
of -X- _ O
humoral -X- _ O
immune -X- _ O
responses. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
using -X- _ O
OVA -X- _ O
as -X- _ O
a -X- _ O
model -X- _ O
Ag -X- _ O
, -X- _ O
we -X- _ O
assessed -X- _ O
the -X- _ O
magnitude -X- _ O
of -X- _ O
the -X- _ O
primary -X- _ O
and -X- _ O
anamnestic -X- _ O
Ag–specific -X- _ O
IgG -X- _ O
responses -X- _ O
of -X- _ O
mice -X- _ B-Patient
to -X- _ O
four -X- _ O
clinically -X- _ O
relevant -X- _ O
vaccine -X- _ O
formulations -X- _ O
: -X- _ O
replication-deficient -X- _ B-Intervention
adenovirus -X- _ I-Intervention
; -X- _ O
modified -X- _ B-Intervention
vaccinia -X- _ I-Intervention
Ankara -X- _ I-Intervention
( -X- _ I-Intervention
a -X- _ I-Intervention
poxvirus -X- _ I-Intervention
) -X- _ I-Intervention
; -X- _ O
protein -X- _ B-Intervention
with -X- _ I-Intervention
alum -X- _ I-Intervention
; -X- _ O
and -X- _ O
protein -X- _ B-Intervention
in -X- _ I-Intervention
the -X- _ I-Intervention
squalene -X- _ I-Intervention
oil-in-water -X- _ I-Intervention
adjuvant -X- _ I-Intervention
Addavax. -X- _ I-Intervention
We -X- _ O
then -X- _ O
used -X- _ O
flow -X- _ O
cytometric -X- _ O
assays -X- _ O
capable -X- _ O
of -X- _ O
measuring -X- _ O
total -X- _ O
and -X- _ O
Ag-specific -X- _ O
germinal -X- _ O
center -X- _ O
( -X- _ O
GC -X- _ O
) -X- _ O
B -X- _ O
cell -X- _ O
and -X- _ O
follicular -X- _ O
Th -X- _ O
cell -X- _ O
responses -X- _ O
to -X- _ O
compare -X- _ O
the -X- _ O
induction -X- _ O
of -X- _ O
these -X- _ O
responses -X- _ O
by -X- _ O
the -X- _ O
different -X- _ O
formulations. -X- _ O
We -X- _ O
report -X- _ O
that -X- _ O
adenovirus -X- _ B-Outcome
vectored -X- _ I-Outcome
vaccines -X- _ I-Outcome
induce -X- _ I-Outcome
Ag -X- _ I-Outcome
insert–specific -X- _ I-Outcome
GC -X- _ I-Outcome
B -X- _ I-Outcome
cell -X- _ I-Outcome
and -X- _ I-Outcome
Ab -X- _ I-Outcome
responses -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
magnitude -X- _ I-Outcome
comparable -X- _ I-Outcome
to -X- _ I-Outcome
those -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
a -X- _ I-Outcome
potent -X- _ I-Outcome
protein -X- _ I-Outcome
/ -X- _ I-Outcome
squalene -X- _ I-Outcome
oil-in-water -X- _ I-Outcome
formulation -X- _ I-Outcome
whereas—despite -X- _ O
a -X- _ O
robust -X- _ O
overall -X- _ O
GC -X- _ O
response—the -X- _ B-Outcome
insert-specific -X- _ I-Outcome
GC -X- _ I-Outcome
B -X- _ I-Outcome
cell -X- _ I-Outcome
and -X- _ I-Outcome
Ab -X- _ I-Outcome
responses -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
modified -X- _ I-Outcome
vaccinia -X- _ I-Outcome
Ankara -X- _ I-Outcome
were -X- _ I-Outcome
extremely -X- _ I-Outcome
weak. -X- _ I-Outcome
Ag-specific -X- _ O
follicular -X- _ O
Th -X- _ O
cell -X- _ O
responses -X- _ O
to -X- _ O
adenovirus -X- _ O
vectored -X- _ O
vaccines -X- _ O
exceeded -X- _ O
those -X- _ O
induced -X- _ O
by -X- _ O
other -X- _ O
platforms -X- _ O
at -X- _ O
day -X- _ O
7 -X- _ O
after -X- _ O
immunization. -X- _ O
We -X- _ O
found -X- _ O
little -X- _ O
evidence -X- _ O
that -X- _ O
innate -X- _ O
immune -X- _ O
activation -X- _ O
by -X- _ O
adenovirus -X- _ O
may -X- _ O
act -X- _ O
as -X- _ O
an -X- _ O
adjuvant -X- _ O
in -X- _ O
such -X- _ O
a -X- _ O
manner -X- _ O
that -X- _ O
the -X- _ O
humoral -X- _ O
response -X- _ O
to -X- _ O
a -X- _ O
recombinant -X- _ O
protein -X- _ O
may -X- _ O
be -X- _ O
enhanced -X- _ O
by -X- _ O
coadministering -X- _ O
with -X- _ O
an -X- _ O
adenovirus -X- _ O
lacking -X- _ O
a -X- _ O
transgene -X- _ O
of -X- _ O
interest. -X- _ O
Overall -X- _ O
, -X- _ O
these -X- _ O
studies -X- _ O
provide -X- _ O
further -X- _ O
support -X- _ O
for -X- _ O
the -X- _ O
use -X- _ B-Outcome
of -X- _ I-Outcome
replication-deficient -X- _ I-Outcome
adenoviruses -X- _ I-Outcome
to -X- _ I-Outcome
induce -X- _ I-Outcome
humoral -X- _ I-Outcome
responses -X- _ I-Outcome
. -X- _ O

